Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.40 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.38 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10888 | 0.91 | NPC1 (0.41) | NPC1L3MBTL3GNAI3GNAO1GNAI1 | |
| SCHEMBL11909639 | 0.91 | NPC1 (0.41) | NPC1L3MBTL3GNAI3GNAO1GNAI1 | |
| SCHEMBL13226743 | 0.81 | NPC1 (0.50) | NPC1GNAI3GNAO1GNAI1ATM | |
| SCHEMBL11080 | 0.81 | GNAI3 (0.55) | NPC1L3MBTL3GNAI3GNAO1GNAI1 | |
| SCHEMBL11410 | 0.80 | NPC1 (0.40) | NPC1GNAI3GNAO1GNAI1MEN1 | |
| SCHEMBL8306572 | 0.80 | NPC1 (0.51) | NPC1L3MBTL3GNAI3GNAO1GNAI1 | |
| SCHEMBL7808404 | 0.80 | NPC1 (0.51) | NPC1L3MBTL3GNAI3GNAO1GNAI1 | |
| SCHEMBL13206742 | 0.79 | NPC1 (0.47) | NPC1GNAI3GNAO1GNAI1ATM | |
| SCHEMBL7806938 | 0.78 | NPC1 (0.50) | NPC1L3MBTL3GNAI3GNAO1GNAI1 | |
| SCHEMBL7804889 | 0.78 | NPC1 (0.50) | NPC1L3MBTL3GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20160264583-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2016-09-15 | — | — | US | disclosed |
| US-20160264583-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2016-09-15 | — | — | US | disclosed |
| US-9321773-B2 | Compounds | Respivert, Ltd. (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20140249164-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2014-09-04 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| EP-2491037-B1 | QUINAZOLIN-4(3H)-ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264583-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | NPC1 492/4885L3MBTL3 4483/4885GNAI3 2090/4885 |
| US-20140249164-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | NPC1 492/4885L3MBTL3 4483/4885GNAI3 2090/4885 |
| US-20120208799-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | NPC1 492/4885L3MBTL3 4483/4885GNAI3 2090/4885 |
| US-20180118754-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | NPC1 492/4885L3MBTL3 4483/4885GNAI3 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.